Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection

Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04542876

Enrollment

Registered

2020-09-09

Start date

2020-05-01

Completion date

2020-08-18

Last updated

2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The emergence of asymptomatic patients poses a significant challenge to the prevention and treatment of the epidemic.There have not been any treatment options that reduce the viral load or preventive options that reduce the risk of developing severe conditions.Therefore, present feasibility study of the safety and efficacy of Guduchi Ghan Vati was conducted in asymptomatic patients with COVID-19

Interventions

DRUGGuduchi Ghan Vati

Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All hospitalised cases above 18 years of age, * Diagnosed with Covid-19 * Asymptomatic at the time of admission * Agree to give consent

Exclusion criteria

* Symptoms relating to Covid-19 * Severe vomiting * Respiratory failure or requiring mechanical ventilation * Patients having alanine transaminase (ALT) or aspartate transaminase (AST) \> 5 times the upper range of normal limits * Patients with Covid-19 in critical condition or ARDS or NIAD 8 -point ordinal score-2 * Patients with uncontrolled diabetes mellitus * Malignant, * Chronic renal failure or * On immunosuppressive medication

Design outcomes

Primary

Measure	Time frame	Description
Virologic clearance	14 days	Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result

Secondary

Measure	Time frame	Description
Hospital Stay	14 days	Total duration of stay in hospital for complete recovery
Clinically relevant adverse effects	14 days	Clinically relevant adverse effects of Guduchi Ghan Vati were reported using Adverse Drug Reaction reporting form
Laboratory tests	change from baseline to 14 days	Routine blood tests were performed to assess complete blood counts, blood biochemistry parameters {Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Urea, C-reactive protein (CRP), as well as Albumin} and immunoglobulines.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026